Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Serum biomarkers of hypoxic-ischemic brain injury

A. Tefr Faridová, H. Heřman, Š. Danačíková, J. Svoboda, J. Otáhal

. 2023 ; 72 (Suppl. 5) : S461-S474. [pub] 20231229

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24003908

Brain injury is a multifaceted condition arising from nonspecific damage to nervous tissue. The resulting cognitive developmental impairments reverberate through patients' lives, affecting their families, and even the broader economic landscape. The significance of early brain injury detection lies in its potential to stave off severe consequences and enhance the effectiveness of tailored therapeutic interventions. While established methods like neuroimaging and neurophysiology serve as valuable diagnostic tools, their demanding nature restricts their accessibility, particularly in scenarios such as small hospitals, nocturnal or weekend shifts, and cases involving unstable patients. Hence, there is a pressing need for more accessible and efficient diagnostic avenues. Among the spectrum of brain injuries, hypoxic-ischemic encephalopathy stands out as a predominant affliction in the pediatric population. Diagnosing brain injuries in newborns presents challenges due to the subjective nature of assessments like Apgar scores and the inherent uncertainty in neurological examinations. In this context, methods like magnetic resonance and ultrasound hold recommendations for more accurate diagnosis. Recognizing the potential of serum biomarkers derived from blood samples, this paper underscores their promise as a more expedient and resource-efficient means of assessing brain injuries. The review compiles current insights into serum biomarkers, drawing from experiments conducted on animal models as well as human brain pathologies. The authors aim to elucidate specific characteristics, temporal profiles, and the available corpus of experimental and clinical data for serum biomarkers specific to brain injuries. These include neuron-specific enolase (NSE), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), S100 calcium-binding protein beta (S100B), glial fibrillary acidic protein (GFAP), and high-mobility-group-protein-box-1 (HMGB1). This comprehensive endeavor contributes to advancing the understanding of brain injury diagnostics and potential avenues for therapeutic intervention.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24003908
003      
CZ-PrNML
005      
20250409105514.0
007      
ta
008      
240305s2023 xr f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.935214 $2 doi
035    __
$a (PubMed)38165751
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Tefr Faridová, Adéla $u Department of Pathophysiology, The Second Faculty of Medicine, Charles University, Prague, Czech Republic, $7 xx0239484 $u The Institute for Mother and Child Care in Prague, Prague, Czech Republic
245    10
$a Serum biomarkers of hypoxic-ischemic brain injury / $c A. Tefr Faridová, H. Heřman, Š. Danačíková, J. Svoboda, J. Otáhal
520    9_
$a Brain injury is a multifaceted condition arising from nonspecific damage to nervous tissue. The resulting cognitive developmental impairments reverberate through patients' lives, affecting their families, and even the broader economic landscape. The significance of early brain injury detection lies in its potential to stave off severe consequences and enhance the effectiveness of tailored therapeutic interventions. While established methods like neuroimaging and neurophysiology serve as valuable diagnostic tools, their demanding nature restricts their accessibility, particularly in scenarios such as small hospitals, nocturnal or weekend shifts, and cases involving unstable patients. Hence, there is a pressing need for more accessible and efficient diagnostic avenues. Among the spectrum of brain injuries, hypoxic-ischemic encephalopathy stands out as a predominant affliction in the pediatric population. Diagnosing brain injuries in newborns presents challenges due to the subjective nature of assessments like Apgar scores and the inherent uncertainty in neurological examinations. In this context, methods like magnetic resonance and ultrasound hold recommendations for more accurate diagnosis. Recognizing the potential of serum biomarkers derived from blood samples, this paper underscores their promise as a more expedient and resource-efficient means of assessing brain injuries. The review compiles current insights into serum biomarkers, drawing from experiments conducted on animal models as well as human brain pathologies. The authors aim to elucidate specific characteristics, temporal profiles, and the available corpus of experimental and clinical data for serum biomarkers specific to brain injuries. These include neuron-specific enolase (NSE), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), S100 calcium-binding protein beta (S100B), glial fibrillary acidic protein (GFAP), and high-mobility-group-protein-box-1 (HMGB1). This comprehensive endeavor contributes to advancing the understanding of brain injury diagnostics and potential avenues for therapeutic intervention.
650    _2
$a novorozenec $7 D007231
650    _2
$a lidé $7 D006801
650    _2
$a dítě $7 D002648
650    12
$a mozková hypoxie a ischemie $x diagnostické zobrazování $7 D020925
650    12
$a poranění mozku $7 D001930
650    _2
$a biologické markery $7 D015415
650    _2
$a thiolesterasa ubikvitinu $7 D043222
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Heřman, Hynek, $d 1972- $7 xx0073991 $u The Institute for Mother and Child Care in Prague, Prague, Czech Republic
700    1_
$a Danačíková, Šárka $u Department of Developmental Epileptology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic $7 xx0331027
700    1_
$a Svoboda, Jan, $u Department of Developmental Epileptology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic $d 1977- $7 xx0145180
700    1_
$a Otáhal, Jakub $u Department of Pathophysiology, The Second Faculty of Medicine, Charles University, Prague, Czech Republic, $u Department of Developmental Epileptology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic $7 xx0105144
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 72, Suppl. 5 (2023), s. S461-S474
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38165751 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20240305 $b ABA008
991    __
$a 20250409105509 $b ABA008
999    __
$a ok $b bmc $g 2298747 $s 1213660
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 72 $c Suppl. 5 $d S461-S474 $e 20231229 $i 1802-9973 $m Physiological research $n Physiol Res $x MED00003824
LZP    __
$b NLK116 $a Pubmed-20240305

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...